Cargando…

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer

Acquisition of mesenchymal properties by cancer cells is critical for their malignant behaviour, but regulators of the mesenchymal molecular machinery and how it is activated remain elusive. Here we show that clear cell renal cell carcinomas (ccRCCs) frequently utilize the Arf6-based mesenchymal pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hashimoto, Shigeru, Mikami, Shuji, Sugino, Hirokazu, Yoshikawa, Ayumu, Hashimoto, Ari, Onodera, Yasuhito, Furukawa, Shotaro, Handa, Haruka, Oikawa, Tsukasa, Okada, Yasunori, Oya, Mototsugu, Sabe, Hisataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748122/ https://www.ncbi.nlm.nih.gov/pubmed/26854204 http://dx.doi.org/10.1038/ncomms10656

Ejemplares similares

P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistance
por: Hashimoto, Ari, et al.
Publicado: (2016)

Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells
por: Handa, Haruka, et al.
Publicado: (2018)

Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model
por: Otsuka, Yutaro, et al.
Publicado: (2018)

ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance
por: Hashimoto, A, et al.
Publicado: (2016)

Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells
por: Handa, Haruka, et al.
Publicado: (2017)

ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019)

ARF1 recruits RAC1 to leading edge in neutrophil chemotaxis
por: Mazaki, Yuichi, et al.
Publicado: (2017)

Necessity of p53-binding to the CDH1 locus for its expression defines two epithelial cell types differing in their integrity
por: Oikawa, Tsukasa, et al.
Publicado: (2018)

The EGFR-GEP100-Arf6-AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis(†)
por: Sabe, Hisataka, et al.
Publicado: (2009)

Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer
por: Hashimoto, Ari, et al.
Publicado: (2021)

High expression of EPB41L5, an integral component of the Arf6-driven mesenchymal program, correlates with poor prognosis of squamous cell carcinoma of the tongue
por: Otsuka, Yutaro, et al.
Publicado: (2016)

High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
por: Tsutaho, Akio, et al.
Publicado: (2020)

Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe
por: Onodera, Yasuhito, et al.
Publicado: (2018)

Rab5c promotes AMAP1–PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion
por: Onodera, Yasuhito, et al.
Publicado: (2012)

GEP100-Arf6-AMAP1-Cortactin Pathway Frequently Used in Cancer Invasion Is Activated by VEGFR2 to Promote Angiogenesis
por: Hashimoto, Ari, et al.
Publicado: (2011)

Co-Overexpression of GEP100 and AMAP1 Proteins Correlates with Rapid Local Recurrence after Breast Conservative Therapy
por: Kinoshita, Rumiko, et al.
Publicado: (2013)

Pag3/Papα/Kiaa0400, a Gtpase-Activating Protein for Adp-Ribosylation Factor (Arf), Regulates Arf6 in Fcγ Receptor–Mediated Phagocytosis of Macrophages
por: Uchida, Hiroshi, et al.
Publicado: (2001)

Engagement of Overexpressed Her2 with GEP100 Induces Autonomous Invasive Activities and Provides a Biomarker for Metastases of Lung Adenocarcinoma
por: Menju, Toshi, et al.
Publicado: (2011)

KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion
por: Sabe, Hisataka
Publicado: (2023)

Dual roles of AMAP1 in the transcriptional regulation and intracellular trafficking of carbonic anhydrase IX
por: Horikawa, Mei, et al.
Publicado: (2021)

p53-Dependent and -Independent Epithelial Integrity: Beyond miRNAs and Metabolic Fluctuations
por: Oikawa, Tsukasa, et al.
Publicado: (2018)

Cross-disease communication between cancer and heart failure provides a rational approach to prevention and treatment of both diseases
por: Takada, Shingo, et al.
Publicado: (2022)

AMAP1 as a negative-feedback regulator of nuclear factor-κB under inflammatory conditions
por: Tien, Dat Nguyen, et al.
Publicado: (2014)

Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma
por: Hashimoto, Ari, et al.
Publicado: (2022)

GBF1 bears a novel phosphatidylinositol-phosphate binding module, BP3K, to link PI3Kγ activity with Arf1 activation involved in GPCR-mediated neutrophil chemotaxis and superoxide production
por: Mazaki, Yuichi, et al.
Publicado: (2012)

Radiologic features of mixed epithelial and stromal tumors of the kidney: Hyperattenuating on unenhanced computed tomography and T2-hypointensity on magnetic resonance imaging
por: Tatsuya, Suzuki, et al.
Publicado: (2021)

EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial–mesenchymal transition
por: Hirano, Mariko, et al.
Publicado: (2008)

High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients
por: Sato, Hiroki, et al.
Publicado: (2014)

LRRK2 is involved in the chemotaxis of neutrophils and differentiated HL-60 cells, and the inhibition of LRRK2 kinase activity increases fMLP-induced chemotactic activity
por: Mazaki, Yuichi, et al.
Publicado: (2023)

Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin
por: Ide, Hiroki, et al.
Publicado: (2014)

Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin
por: Fukumoto, Keishiro, et al.
Publicado: (2016)

2-Carba-lysophosphatidic acid is a novel β-lysophosphatidic acid analogue with high potential for lysophosphatidic acid receptor activation and autotaxin inhibition
por: Fukasawa, Keiko, et al.
Publicado: (2021)

A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient
por: Kaneko, Yuta, et al.
Publicado: (2022)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management
por: Jinzaki, Masahiro, et al.
Publicado: (2014)

Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers
por: Fukumoto, Keishiro, et al.
Publicado: (2016)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer
por: Hagiwara, Masayuki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0aqtu6k1og7p1dr29n9gt1ei50